Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Illumina Ventures

BioCentury | Jan 15, 2025
Emerging Company Profile

Mursla: Using extracellular vesicles to detect cancer

Led by former banker Pierre Arsène, the start-up’s first goal is surveillance of cirrhosis patients at risk of liver cancer
BioCentury | May 9, 2024
Finance

Venture report: Big rounds for Bluejay, Attovia and Zenas

Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Oct 19, 2023
Regulation

Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq

Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Oct 6, 2023
Regulation

Oct. 5 Quick Takes: FDA panel declines to back Lumakras

Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Oct 5, 2023
Regulation

Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma

Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Sep 19, 2023
Product Development

Sept. 18 Quick Takes: Anthos’ mAb meets Phase II bleeding endpoint

Plus: Priority review for Orchard’s ex vivo gene therapy and more from BioNTech, Broken String and FDA
BioCentury | Aug 18, 2023
Finance

Aug. 17 Quick Takes: China tools play Sangon attracts Novo Holdings in $290M round

Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA
BioCentury | Jun 21, 2023
Emerging Company Profile

Attovia: improving affinity and specificity using linked nanobodies

Alamar spinout Attovia is linking single heavy chain antibody pairs to double down on difficult therapeutic targets for cancer and immune diseases
BioCentury | Jun 2, 2023
Emerging Company Profile

Actym: programming microbes to treat solid tumors

Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
BioCentury | Apr 27, 2023
Finance

April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies

Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
Items per page:
1 - 10 of 54